3 Weight-Loss ETFs to Profit From the Obesity Drug Boom

InvestorPlace04-17

Gain from the healthcare evolution driven by high-profile endorsements of new weight management drugs. iShares US Healthcare Providers ETF (IHF): Grew 11% last year, supported by endorsements of drugs...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428395355?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-17 16:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428395355","market":"us","top_or_hot":-1,"title":"3 Weight-Loss ETFs to Profit From the Obesity Drug Boom","media":"InvestorPlace","content":"<div>\n<p>Gain from the healthcare evolution driven by high-profile endorsements of new weight management drugs.\niShares US Healthcare Providers ETF (IHF): Grew 11% last year, supported by endorsements of drugs...</p>\n\n<a href=\"https://investorplace.com/2024/04/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Weight-Loss ETFs to Profit From the Obesity Drug Boom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Weight-Loss ETFs to Profit From the Obesity Drug Boom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 16:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/04/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gain from the healthcare evolution driven by high-profile endorsements of new weight management drugs.\niShares US Healthcare Providers ETF (IHF): Grew 11% last year, supported by endorsements of drugs...</p>\n\n<a href=\"https://investorplace.com/2024/04/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://investorplace.com/2024/04/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom/","article_id":"2428395355","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428395355","pubTimestamp":1713342636,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc",".IXIC":"NASDAQ Composite","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4551":"寇图资本持仓","HUM":"哈门那","TNDM":"糖尿病保健","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","PPH":"VanEck Pharmaceutical ETF","PODD":"银休特","QLD":"纳指两倍做多ETF","NVO":"诺和诺德","PSQ":"纳指反向ETF","CVS":"西维斯健康","FDN":"First Trust Dow Jones Internet I","LLY":"礼来","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","CI":"信诺保险","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","TQQQ":"纳指三倍做多ETF","HLF":"康宝莱","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","QQQ":"纳指100ETF","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","UNH":"联合健康","DXCM":"德康医疗","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","SLIM":"The Obesity ETF","IHF":"iShares Dow Jones U.S. Health Ca","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","BK4566":"资本集团","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","QID":"纳指两倍做空ETF","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","SQQQ":"纳指三倍做空ETF","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC"},"translate_title":"3减肥ETF从肥胖药物热潮中获利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNH":1,"LLY":1,"IHF":1,"NVO":1,"PODD":1,"PPH":1,"HUM":1,"HLF":1,"SLIM":1,"DXCM":1,"CVS":1,"CI":1,"TNDM":1,"FDN":0.9,".IXIC":0.9,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Gain from the healthcare evolution driven by high-profile endorsements of new weight management drugs.\niShares US Healthcare Providers ETF (IHF): Grew 11% last year, supported by endorsements of drugs like Ozempic; stable with a 0.72 beta and 0.78% dividend yield.\nThe Obesity ETF (SLIM): Despite an 11% drop in YTD, SLIM invests heavily in obesity and diabetes care, prominently featuring Novo Nordisk (NVO).\nVanEck Pharmaceutical ETF (PPH): Up 7% this year, PPH focuses on weight-loss pharmaceuticals, including Eli Lilly’s (LLY) Mounjaro, which promises up to 20% weight reduction.\n\n\n\n\n\n \n\nSource: Hernan E. Schmidt / Shutterstock.com\n\n\n\nPeople are interested in ETFs for weight loss because of Oprah’s TV show “Shame, Blame, and the Weight Loss Revolution,” which was about weight loss drugs. A lot of people are upset that she’s talking to patients and doctors about using prescription drugs to lose weight, but it’s still causing a stir.\nIt’s also big news that Oprah is leaving the Weight Watchers board. The fact that she backs drugs like Mounjaro, Wegovy and Ozempic shows how times are changing for everyone. It’s always been hard for the famous talk show host to lose weight. But because she was so famous, everything she suggested to lose weight sold out very quickly.\nIn other words, we see the same pattern with drugs that help people lose weight. Because of Oprah’s ABC special, the dieting business and the practice of dieting are changing. This is like what happened when she really tried to lose weight in 1998. The only difference is the methodology she’s adopting.\nBut be careful while Oprah fights the social shame that comes with losing weight with Ozempic. Not only does Ozempic have side effects, but a lot of new medicines need testing.\nThen, what is the safest thing to do with this trend? Investing in the best exchange-traded funds (ETFs) for weight loss can open up a lot of health and fitness-related doors for you. While Oprah plugs diet pills, let’s look at three exchange-traded funds that can help you lose weight.\niShares US Healthcare Providers ETF (IHF)\nSource: ShutterstockThe iShares US Healthcare Providers ETF (NYSEARCA:IHF), up 11% in the past year, boasts a competitive expense ratio of 0.40% and a dividend yield of 0.78%. It is riding the Oprah momentum, which is turning back the clock to the late 90s. \nThe expense ratio indicates the amount you will pay to own a fund over the course of a year. In this case, it is pretty reasonable, meaning there are no complaints to management. The yield might seem a bit ordinary, but this is an ETF we are talking about.\nAt the end of last year, IHF divided its shares five-to-one to reduce their value and increase the number of outstanding shares, which improved accessibility. \nOne of the oldest weight-loss ETFs available, IHF focuses on the healthcare and nursing home industries and tracks the Dow Jones U.S. Select Health Care Providers Index.\nIts reduced volatility in correlation with the market overall as a whole gives it the attributes of medium risk, which exhibits a beta of 0.72 and standard deviation of 17.20% over a 3-year historical time period.\nIHF’s portfolio’s top holdings, UnitedHealth Group (NYSE:UNH), CVS Health (NYSE:CVS), Cigna (NYSE:CI) and Humana (NYSE:HUM), at 22%, 4%, 10% and 4%, respectively, offer many wellness programs that can ride the current Oprah momentum to the bank. These programs include diet plans from Humana, over-the-counter weight loss supplements at CVS MinuteClinics, nutritional counseling from Cigna and weight management plans through UnitedHealth’s Optum.\nThe Obesity ETF (SLIM)\nSource: WHYFRAME / Shutterstock.comJanus Henderson’s The Obesity ETF (NASDAQ:SLIM) tracks the performance of global companies offering obesity-related services, but the twist is that several fields fall under this category. Just as we saw with IHF, there is no singular way to invest in healthcare, biotechnology, pharmaceuticals, plus-size clothing, weight loss programs and medical devices.\nThe Obesity ETF invests at least 80% of its net assets in the stocks that comprise the Solactive Obesity Index. Its lack of diversity compared to other exchange-traded funds means it may favor investing in specific companies or industries.\nAt $11.63 million in net worth, SLIM offers a dividend yield of 0.57%. The fund’s disastrous losses as of late — a year-to-date total loss of 11.27% — are due to the unpredictable nature of the healthcare industry.\nCompanies involved in treating diabetes and obesity account for about three quarters of SLIM’s assets. Regarding ownership, Novo Nordisk‘s (NYSE:NVO) 20% and DexCom‘s (NASDAQ:DXCM) 13% are at the top.\nAs a weight loss product manufacturer, SLIM owns Novo Nordisk and Herbalife (NYSE:HLF). Obese adults can take one of two weight management medications made by industry giant Novo Nordisk: Wegovy or Saxenda. Among Herbalife’s many health and weight loss aids are protein shakes, bars and teas. It’s worth remembering that Wegovy is a name that has been popping up a lot ever since Oprah decided to create a major cultural boost for these prescription drugs.\nSeveral prominent companies are part of its portfolio, including Tandem Diabetes Care (NASDAQ:TNDM), Insulet Corporation (NASDAQ:PODD), and DexCom. Weight loss aids made by these companies, which boost metabolic health, make managing diabetes easier. Healthcare providers and medical device manufacturers all have an indirect interest in helping with weight management.\nVanEck Pharmaceutical ETF (PPH)\nSource: Dmitry Kalinovsky / Shutterstock.comVanEck Pharmaceutical ETF‘s (NASDAQ:PPH) focus on pharmaceuticals makes for an interesting analysis. It’s the main beneficiary of the Oprah-led boom.\nThe ETF has increased by more than 7% to $85.44 in the last year. Shares are issued and redeemed on demand by this open-ended investment company. On Mar. 31, net assets and share class size totaled $543.2 million.\nWith a net expense ratio of only 0.36%, this shows the fund’s operational expenditures are managed effectively. \nVanEck Pharmaceutical ETF’s portfolio helped develop weight-loss and treatment drugs. Tigepatide, sold as Mounjaro, has made Eli Lilly (NYSE:LLY) a weight loss pharmaceutical giant. Tirzepatide, first approved for type 2 diabetes, regulates hunger and insulin secretion by blocking GLP-1 and GIP receptors. This medication can reduce weight by 20% in overweight or obese non-diabetics.\nNovo Nordisk has benefited from semaglutide, which is sold as Wegovy for obesity and Ozempic for diabetes, two names linked to Oprah and her new attitude toward weight management. This chronic weight management program helps patients lose 15%, making Wegovy famous. \nOn the date of publication, Faizan Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\nFaizan Farooque is a contributing author for InvestorPlace.com and numerous other financial sites. Faizan has several years of experience in analyzing the stock market and was a former data journalist at S&P Global Market Intelligence. His passion is to help the average investor make more informed decisions regarding their portfolio.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/04/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom/.\n©2024 InvestorPlace Media, LLC","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428395355"}